Enlivex Ltd. has announced a significant update regarding its clinical trials for Allocetra™, a treatment aimed at knee osteoarthritis. The independent Data and Safety Monitoring Board (DSMB) has completed an interim safety review of the Phase IIb trial, allowing the company to continue enrolling patients as planned.

This development is crucial as it confirms the safety profile of Allocetra™, which is being evaluated in a randomized, double-blind, placebo-controlled study involving patients with primary age-related knee osteoarthritis. The trial aims to assess the efficacy and safety of the treatment, which is particularly relevant given the increasing prevalence of osteoarthritis among aging populations.

Background

Enlivex Ltd. is a company based in Israel that operates in the finance services sector (SIC: 6199). The company is listed on the Nasdaq under the ticker symbol ENLV. Enlivex focuses on advancing innovative treatments for inflammatory conditions associated with aging, particularly through its clinical-stage immunotherapy, Allocetra™. Recent filings indicate consistent activity in the company's clinical programs, reflecting its commitment to developing effective therapies.

What the Filing Says

According to the filing dated November 18, 2026, the DSMB's review covered data from 85 patients who were randomized and dosed in the trial. The board confirmed that the safety profile of Allocetra™ is satisfactory, allowing the company to proceed with patient enrollment. Chief Medical Officer Einat Galamidi expressed satisfaction with the DSMB's decision, stating, "We are pleased with the DSMB’s decision that the trial will continue as planned and designed." This statement underscores the company's confidence in the trial's design and the potential of Allocetra™.

Impact

This positive interim review is likely to affect various stakeholders, including patients seeking effective treatments for knee osteoarthritis, healthcare providers, and investors interested in the company's progress. The trial's focus on an aging demographic highlights the urgent need for new therapies in this area, especially as osteoarthritis remains a leading cause of disability worldwide.

What's Next

The filing does not specify what happens next, but the continuation of patient enrollment in the Phase IIb trial is expected as the company moves forward with its clinical program. Enlivex will likely keep stakeholders updated on further developments and topline data from the trial as it progresses.